Secondary prevention for coronary artery disease: are we following the guidelines?
AffiliationWaterford Regional Hospital, Waterford, Ireland. firstname.lastname@example.org
MeSHAdrenergic beta-Antagonists/administration & dosage
Angiotensin-Converting Enzyme Inhibitors/administration & dosage
Coronary Artery Disease/drug therapy/*prevention & control
Guideline Adherence/*statistics & numerical data
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
Physician's Practice Patterns/*statistics & numerical data
*Practice Guidelines as Topic
MetadataShow full item record
CitationIr J Med Sci. 2010 Dec;179(4):535-7. Epub 2010 Jul 31.
JournalIrish journal of medical science
AbstractBACKGROUND: Secondary prevention pharmacotherapy in post-myocardial infarction (MI) patients reduces the risk of subsequent coronary events and overall mortality. International guidelines recommend use of aspirin, beta-blockers, ACE inhibitors and statins in post-MI patients. AIMS: We performed this audit to review the compliance of prescribing practices, in a regional hospital in Ireland, with international guidelines for secondary prevention of coronary artery disease. METHODS: We performed a retrospective case review of 172 patients diagnosed with MI during a 1-year period between January and December 2007. RESULTS: A total of 134 patients fulfilled the inclusion criteria. On discharge, aspirin was prescribed to 131 (97.76%) patients, clopidogrel to 126 (94%), beta-blockers to 117 (87%), ACE inhibitor to 87 (65%), ARB to 10 (7%) and statins to 116 (87%). CONCLUSION: Our audit shows that targets for prescription of secondary prevention medications were not met in a small but significant proportion of patients and calls for review of discharge practices and education to improve compliance with guidelines.
- Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
- Authors: Apikoglu Rabus S, Izzettin FV, Sancar M, Karakaya O, Kargin R, Yakut C
- Issue date: 2008 Dec
- Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
- Authors: Lee HY, Cooke CE, Robertson TA
- Issue date: 2008 Apr
- Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
- Authors: El-Hajj MS, Saad A, Al-Suwaidi J, Al-Marridi WZ, Elkhalifa DH, Mohamed AA, Mahfoud ZR
- Issue date: 2016
- Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
- Authors: Sharma KK, Gupta R, Agrawal A, Roy S, Kasliwal A, Bana A, Tongia RK, Deedwania PC
- Issue date: 2009
- Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
- Authors: Underwood P, Beck P
- Issue date: 2002 Sep